Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 17.65 percent. This is unchanged from the same period last year. The company reported quarterly sales of $20.018 million which beat the analyst consensus estimate of $18.463 million by 8.42 percent. This is a 11.68 percent increase over sales of $17.925 million the same period last year.